An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.
Source: https://medicalxpress.com/news/2026-02- ... -clot.html
-
Translation